Clarivate Epidemiology’s coverage of systemic lupus erythematosus (SLE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate Epidemiology’s coverage of OPE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of OPE for each country, as well as…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key OPE patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of erectile dysfunction comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
The treatment landscape for COVID-19 continues to evolve rapidly. Even with vaccines having become available in the markets under study, intense ongoing research has also focused on approaches…
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…
The number of diagnosed prevalent cases of SCA in the countries under study will increase by 10% over the 20-year forecast period, from 29,000 to 32,000. Of the countries considered in this…
Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as…